These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22761158)

  • 41. Immediate hypersensitivity reaction to single-dose parenteral ceftriaxone therapy for gonorrhea.
    Zishka PA; Douglas JM
    Sex Transm Dis; 1991; 18(1):26-7. PubMed ID: 2028365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Anaphylactic shock associated with ceftriaxone therapy in a newborn].
    Baumgartner-Bonnevay C; Choquet-Kastylevsky G; Putet G; Bleyzac N; Vial T; Descotes J
    Arch Pediatr; 2002 Oct; 9(10):1050-2. PubMed ID: 12462836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physical Incompatibility Between Protamine Sulfate and Ceftriaxone Sodium.
    Gupta D; Soori R
    J Cardiothorac Vasc Anesth; 2017 Jun; 31(3):e50-e51. PubMed ID: 28365138
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluating Ceftriaxone 80 mg/kg Administration by Rapid Intravenous Infusion-A Clinical Service Evaluation.
    Patel S; Green H; Gray J; Rutter M; Bevan A; Hand K; Jones CE; Faust SN
    Pediatr Infect Dis J; 2021 Feb; 40(2):128-129. PubMed ID: 33165272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.
    Donnelly PC; Sutich RM; Easton R; Adejumo OA; Lee TA; Logan LK
    Paediatr Drugs; 2017 Feb; 19(1):21-34. PubMed ID: 27718120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Influence of the Parameter "The Rate of Administration" During the Test "Abnormal Toxicity" on Quality Control of Ceftriaxone an Antibiotic of the Cephalosporin Group].
    Sharoykina MV; Ryabtseva MS; Kovaleva EL; Neugodova NP
    Antibiot Khimioter; 2015; 60(1-2):35-8. PubMed ID: 26168683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.
    Kang MH; Villablanca JG; Glade Bender JL; Matthay KK; Groshen S; Sposto R; Czarnecki S; Ames MM; Reynolds CP; Marachelian A; Maurer BJ
    BMC Res Notes; 2014 Apr; 7():256. PubMed ID: 24755475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kounis syndrome: acute inferior myocardial infarction with atroventricular node block due to ceftriaxone: a first reported case.
    Saleh AA
    Ann Saudi Med; 2014; 34(3):250-3. PubMed ID: 25266187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of a potential clinical interaction between ceftriaxone and calcium.
    Steadman E; Raisch DW; Bennett CL; Esterly JS; Becker T; Postelnick M; McKoy JM; Trifilio S; Yarnold PR; Scheetz MH
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1534-40. PubMed ID: 20086152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment.
    Puri BK; Derham A; Monro JA
    Rev Recent Clin Trials; 2018; 13(4):287-294. PubMed ID: 29769008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia.
    Arnet I; Altermatt M; Roggo Y; Schnetzler G
    J Chemother; 2015; 27(6):337-42. PubMed ID: 25144924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population-based studies of adverse drug effects.
    Ray WA
    N Engl J Med; 2003 Oct; 349(17):1592-4. PubMed ID: 14573730
    [No Abstract]   [Full Text] [Related]  

  • 53. Ceftriaxone-induced toxic hepatitis.
    Peker E; Cagan E; Dogan M
    World J Gastroenterol; 2009 Jun; 15(21):2669-71. PubMed ID: 19496200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftriaxone-induced pseudolithiasis: not just a theoretical risk.
    Fan L; Lau P; Kapur J; Karthik SV
    Singapore Med J; 2017 Nov; 58(11):676-677. PubMed ID: 29167906
    [No Abstract]   [Full Text] [Related]  

  • 55. Ceftriaxone-associated encephalopathy in a patient with high levels of ceftriaxone in blood and cerebrospinal fluid.
    Nishioka H; Cho Y; Irie K; Kanamori M
    Int J Infect Dis; 2022 Mar; 116():223-225. PubMed ID: 35063677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.
    Tam VH; Cohen DN; Ledesma KR; Guillory B; Chan K; Garey KW
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hazards of rapid administration of ceftriaxone.
    Lossos IS; Lossos A
    Ann Pharmacother; 1994 Jun; 28(6):807-8. PubMed ID: 7919578
    [No Abstract]   [Full Text] [Related]  

  • 58. The Role of an Impurity in Ceftriaxone Sodium Preparation for Injection in Determining Compatibility with Calcium-Containing Solutions.
    Tange M; Yoshida M; Nakai Y; Uchida T
    Chem Pharm Bull (Tokyo); 2016; 64(3):207-14. PubMed ID: 26936047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug interaction software and the risk of using ceftriaxone with therapeutic hemapheresis.
    Motroni M; Reilly C
    Am J Health Syst Pharm; 2009 Sep; 66(17):1518-9. PubMed ID: 19710432
    [No Abstract]   [Full Text] [Related]  

  • 60. Ceftriaxone by IV push.
    Agunbiade A; Routsolias JC; Moskoff J
    Am J Emerg Med; 2021 Jun; 44():476. PubMed ID: 32741557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.